NCT04283656View on ClinicalTrials.gov

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 4, 2022

Primary Completion Date

October 25, 2022

Study Completion Date

December 30, 2022

Conditions

Transgender HealthGender DysphoriaTransgender WomenHuman Immunodeficiency Virus

Interventions

DRUG

Doravirine/Lamivudine/Tenofovir

100mg/300mg/300mg orally for one dose, daily

DRUG

Spironolactone 100mg

200mg orally for two doses, twice-daily

DRUG

Estradiol 2mg

4mg orally for two doses, twice-daily

OTHER

Placebo

Placebo for one dose, daily

Trial Locations (1)

19107

Clinical Research Unit at Thomas Jefferson University, Philadelphia

All Listed Sponsors

lead

Thomas Jefferson University

OTHER

NCT04283656 - Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women | Biotech Hunter | Biotech Hunter